Vaxcyte (PCVX) Stock: Buy, Sell, or Hold?
PCVX - Vaxcyte, Inc. Common Stock
$63.23
-3.00 (-4.53%)
âŧ
5d:
-6.4%
30d:
+7.13%
90d:
+13.64%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 03, 2026
11d
Get Alerted When PCVX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PCVX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PCVX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PCVX is currently trading at $63.23, which is considered fair relative to its 30-day fair value range of $56.99 to $67.21.
Technical Outlook: Technically, PCVX is in a uptrend. The price is currently testing key support at $62.54. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: PCVX scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $117.30 (+85.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PCVX is in a uptrend. The price is currently testing key support at $62.54. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: PCVX scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $117.30 (+85.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$56.99 -
$67.21
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.5%)
- BULLISH: Trading 85.5% below Wall St target ($117.30)
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$56.99 -
$67.21
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$62.54
Resistance Level
$72.89
Current Trend
Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.88
Wall Street Target
$117.30
(+85.5%)
Share & Embed Analysis
Last updated: October 22, 2026 8:47 AM ET
Data refreshes hourly during market hours. Next update: 9:47 AM
Data refreshes hourly during market hours. Next update: 9:47 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCVX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 56 HOLD |
|
REGN
Regeneron PharmaceuticalâĻ |
BUY
28 analysts |
$864 | 47 HOLD |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
STRONG BUY
20 analysts |
$31 | 71 BUY |
|
ELVN
Enliven Therapeutics Inc. |
STRONG BUY
14 analysts |
$74 | 63 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 53 HOLD |
